These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33930383)

  • 1. The mifepristone REMS: A needless and unlawful barrier to care✰.
    Kaye J; Reeves R; Chaiten L
    Contraception; 2021 Jul; 104(1):12-15. PubMed ID: 33930383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the impact of mifepristone's risk evaluation and mitigation strategy (REMS) on the integration of medication abortion into US family medicine primary care clinics✰,✰✰.
    Razon N; Wulf S; Perez C; McNeil S; Maldonado L; Fields AB; Carvajal D; Logan R; Dehlendorf C
    Contraception; 2022 May; 109():19-24. PubMed ID: 35131289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA preemption of conflicting state drug regulation and the looming battle over abortion medications.
    Grossi P; O'Connor D
    J Law Biosci; 2023; 10(1):lsad005. PubMed ID: 36938304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication abortion: Potential for improved patient access through pharmacies.
    Raifman S; Orlando M; Rafie S; Grossman D
    J Am Pharm Assoc (2003); 2018; 58(4):377-381. PubMed ID: 29752204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abortion exceptionalism and the mifepristone REMS.
    Serpico JJ
    Contraception; 2021 Jul; 104(1):8-11. PubMed ID: 33831445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US clinicians' perspectives on how mifepristone regulations affect access to medication abortion and early pregnancy loss care in primary care.
    Srinivasulu S; Yavari R; Brubaker L; Riker L; Prine L; Rubin SE
    Contraception; 2021 Jul; 104(1):92-97. PubMed ID: 33910031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding access to medication abortion through pharmacy dispensing of mifepristone: Primary care perspectives from Illinois.
    Rasmussen KN; Janiak E; Cottrill AA; Stulberg DB
    Contraception; 2021 Jul; 104(1):98-103. PubMed ID: 33781760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remote Reproductive Rights.
    Rebouché R
    Am J Law Med; 2022 Jul; 48(2-3):244-255. PubMed ID: 36715252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mailing abortion pills does not delay care: A cohort study comparing mailed to in-person dispensing of abortion medications in the United States.
    Koenig LR; Raymond EG; Gold M; Boraas CM; Kaneshiro B; Winikoff B; Coplon L; Upadhyay UD
    Contraception; 2023 May; 121():109962. PubMed ID: 36736715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of abortion is now: Mifepristone by mail and in-clinic abortion access in the United States.
    Mark A; Foster AM; Perritt J
    Contraception; 2021 Jul; 104(1):38-42. PubMed ID: 33844980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suggested FDA restrictions might curtail access to mifepristone.
    Contracept Technol Update; 2000 Aug; 21(8):89-91. PubMed ID: 12349758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mifepristone restrictions and primary care: Breaking the cycle of stigma through a learning collaborative model in the United States.
    Calloway D; Stulberg DB; Janiak E
    Contraception; 2021 Jul; 104(1):24-28. PubMed ID: 33891965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion.
    Gold M; Chong E
    Contraception; 2015 Sep; 92(3):194-6. PubMed ID: 26093187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "It was close enough, but it wasn't close enough": A qualitative exploration of the impact of direct-to-patient telemedicine abortion on access to abortion care.
    Kerestes C; Delafield R; Elia J; Chong E; Kaneshiro B; Soon R
    Contraception; 2021 Jul; 104(1):67-72. PubMed ID: 33933421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates to the US Food and Drug Administration Regulations for Mifepristone: Implications for Clinical Practice and Access to Abortion.
    Simmonds KE; Beal MW; Eagen-Torkko MK
    J Midwifery Womens Health; 2017 May; 62(3):348-352. PubMed ID: 28632953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mifepristone-misoprostol medical abortion: home administration of misoprostol in Guadeloupe.
    Guengant JP; Bangou J; Elul B; Ellertson C
    Contraception; 1999 Sep; 60(3):167-72. PubMed ID: 10640161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "I'll just deal with this on my own": a qualitative exploration of experiences with self-managed abortion in the United States.
    Raifman S; Ralph L; Biggs MA; Grossman D
    Reprod Health; 2021 May; 18(1):91. PubMed ID: 33947413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on medication abortion.
    Beal MW
    J Midwifery Womens Health; 2007; 52(1):23-30. PubMed ID: 17207747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rebound of medication abortion in Texas following updated mifepristone label.
    Baum SE; White K; Hopkins K; Potter JE; Grossman D
    Contraception; 2019 May; 99(5):278-280. PubMed ID: 30684470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mifepristone-misoprostol regimen for early medical abortion.
    Ellertson C; Waldman SN
    Curr Womens Health Rep; 2001 Dec; 1(3):184-90. PubMed ID: 12112968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.